CIA
MRNA icon

CSat Investment Advisory’s Moderna MRNA Stock Holding History

CSat Investment Advisory’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,597
Closed -$184K – 786
2020
Q3 		$184K Buy
2,597
+1,827
+237% +$127K 0.02% 291
2020
Q2 		$49K Buy
+770
New +$42.2K 0.01% 682

Other funds holding MRNA

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CSat Investment Advisory's MRNA Position: Q4 2020 in Review

CSat Investment Advisory sold out of Moderna (MRNA) in Q4 2020, closing a stake of 2,597 shares — an estimated $184K sold.

CSat Investment Advisory first reported a position in MRNA in Q2 2020 and held it in 2 quarters. The position peaked at $184K in Q3 2020. 718 funds tracked by Wall St. Rank hold MRNA as of Q4 2020.

  • CSat Investment Advisory reported no remaining Moderna position as of Q4 2020 after selling out during the quarter.
  • CSat Investment Advisory sold 2,597 Moderna shares in Q4 2020, an estimated $184K.
  • CSat Investment Advisory first reported a position in Moderna in Q2 2020 and held it in 2 quarters.
  • CSat Investment Advisory's Moderna position peaked at $184K in Q3 2020.
  • 718 funds tracked by Wall St. Rank held Moderna as of Q4 2020.

Based on CSat Investment Advisory's 13F filing for Q4 2020, filed 12 Feb 2021.